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The Diagnostic and Statistical Manual of Mental Disorders (DSM) is universally acknowledged as the prominent
reference textbook for the diagnosis and assessment of psychiatric diseases. However, since the publication of its
first version in 1952, controversies have been raised concerning its reliability and validity and the need for other
novel clinical tools has emerged. Currently the DSM is in its fourth edition and a new fifth edition is expected for
release in 2013, in an intense intellectual debate and in a call for new proposals.
Since 1952, psychiatry has undergone many changes and is emerging as unique field in the medical area in which
a novel approach is being demanded for properly treating patients: not the classical “one-size-fits-all” approach, but
a more targeted and tailored diagnosis and therapeutics, taking into account the complex interactions among
genes and their products, environment, culture and the psychological apparatus of the subject.
OMICS sciences, being based on high-throughput technologies, are systems biology related fields (like genomics,
proteomics, transcriptomics and so on). In the frame of the P5 medicine (personalized, participatory, predictive,
preventive, psycho-cognitive), they could establish links between psychiatric diseases, which are disorders with a
final common symptomatology with vastly heterogeneous biological, environmental and sociological
underpinnings, and by understanding the psychiatric diseases beyond their classic symptomatic or syndromal
definitions using OMICS research, one can have a broader picture and unprecedented links and reclassification of
psychiatric nosology. Importantly, by understanding the basis of heterogeneity in diseases through OMICS research,
one could also personalize treatment of psychiatric illnesses.
In this manuscript, we discuss a gap in the current psychiatric research, namely the missing logical link among OMICS,
personalized medicine and reclassification of diseases. Moreover, we explore the importance of incorporating OMICS-
based quantitative dimensional criteria, besides the classical qualitative and categorical approach.
Keywords: Biological psychiatry, Systems biology, Network medicine, Bioinformatics, New psychiatry, Personalized
medicine, DSM-V, OMICSItalian abstract
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reproduction in any medium, provided the orhas been the gold standard to make diagnosis. However
psychiatric diseases are complex, multifaceted and multi-
factorial pathologies, characterized by high heterogeneity
and variance and therefore classical methods have proven
to be too simple or not completely adequate to capture
this complexity [1].
The categorical approach, in fact, suffers from some
drawback, like circular reasoning and ambiguity [2], in
considering diseases such as static categories and discrete
ontologies, separate one from the others. Moreover, it is
very puzzling where to set the boundary between the
“normal” (health status) and the “abnormal” (the disease)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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above all social and political concerns [2].
Another disadvantage of using the categorical approach
alone is the nosological overlap: under the same clinical
umbrella, different diseases with different prognosis can
co-exist. Categorical approach, being qualitative, should
be complemented with a more fine-grained diagnostic
tool. On the other hand, molecular classification can really
help and improve the classical nosological taxonomy and
thus ameliorate the outcome of patient management and
care.
This aspect of integrated psychological and biological
assessment, that is to say both quantitative and qualita-
tive, categorical and dimensional, is to be stressed within
the frame of personalized medicine (P5) and targeted
therapeutics, which recently emerged as promising and
exciting trends. P5 medicine (i.e., predictive, preventive,
personalized, participatory and psycho-cognitive) [3-5]
entails the addition of the psycho-cognitive domain as a
conceptual evolution of P4 medicine, introduced by the
molecular oncologist Leroy Hood [6]. P5 medicine, as
advocated by Gorini, Pravettoni and Ozdemir, has aban-
doned the model of paternalism that characterized the
20th century physician-patient interaction. Instead P5 is
participatory and makes use of models and equations to
predict patient's future health status in order to adopt
the best strategy available (being predictive); is prevent-
ive in being proactive and not merely reactive; and is
psycho-cognitive in that it adopts an integrated model in
which psychological health is seen as a fundamental as-
pect of personal well-being. Psychology plays different
roles in medicine: from the compliance and adherence to
treatment, to the access of the treatment itself (traditional
versus alternative or complementary) and ultimately to
the therapeutic alliance of the broad meaning. The con-
cept of disease is thus shifting from an atheoretical,
context-free, “Platonic” model, to an approach that instead
is more focused on patient's characteristics and needs [5].
While P5 medicine is biology-driven (personalized,
predictive, preventive), it is also psychologically and eth-
ically engaged (psychocognive, participatory). Therefore,
it is really patient-centered.
Thus, psychiatry is emerging as something of a unique
medical field in which a novel approach is demanded
and needed for properly treating patients through a
more targeted and tailored diagnosis and therapy [1-14],
taking into account the complex interactions among
genes and their products, environment, and culture (as
shown in Figure 1).
For this reason, both molecular (studied through novel
biotechnologies such as gene microarrays and/or protein
arrays) and psychodynamic aspects must be considered
in order to fulfill the promises and true potential of a
personalized psychiatry [15,16].Moreover, since its very beginning, psychiatry has
always had societal, ethical and political implications.
The negative stereotypes, social stigma, and host of dis-
criminating policies and discredit have hindered the
process of psychiatric rehabilitation. P5 medicine, being
multi-scalar and multi-dimensional, include the patient as
an actor in the therapeutic process and incorporates
“open knowledge production systems” in a truly holistic
approach, may well capture the original concept of the in-
dividual person to acknowledge the dignity of the patient
in the formulation and application of acts of care [17].From classical qualitative and categorical approaches to
dimensional and integrated approaches
In this first section, we provide a brief overview of the his-
toricity of the main approaches that have been proposed
for a unitary psychiatric taxonomy, emphasizing the shift
from a categorical qualitative approach, to a more refined
dimension methodology.DSM/ICD model
The Diagnostic and Statistic Manual of Mental Disor-
ders (DSM) was originally developed in 1952, upon the
publication of the DSM-I. The DSM represents the first
tool developed for ad hoc psychiatric diagnosis, even
though its sources were implemented for epidemio-
logical and social policy purposes, and not (at least ini-
tially) for the sake of diagnosis and treatment.
It is important to emphasize that DSM is a work in
progress, and has undergone many changes through its
evolution, shifting from a philosophical and phenomeno-
logical approach, to one that is more qualitative and psy-
chometric, incorporating neo-Kraepelinian orientation
(for an overview, the reader is referred to [2]).
The so-called Feighner criteria (and their expanded ver-
sion, the Research Diagnostic Criteria, RDC, of the Na-
tional Institute of Mental Health, NIMH, Psychobiology of
Depression Collaborative Study, in 1978) have been ac-
knowledged as the foundation of the version of DSM-III,
which also incorporated the Robins-Guze criteria (i.e., de-
scribing five phases of psychiatric diagnostic formulation,
namely clinical description, laboratory analysis, exclusion
of other disorders, follow-up and family study) [18].
This same methodology has informed the International
Statistical Classification of Diseases and Related Health
Problems (ICD), developed by World Health Organization
(WHO), while the Psycho-dynamic Diagnostic Manual
(PDM) remains the psychoanalytical counterpart [19].
Although it was greatly improved throughout its dif-
ferent versions, problems persist in the DSM. Among
the main limitations are the arbitrary threshold for diag-
nosis, the lack of quantitative criteria, potential abuse
and/or misuse of the not otherwise specified (NOS)
Figure 1 Triangle showing interactions among human genome, environment and culture in the pathogenesis of psychiatric diseases.
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axial structure (i.e., the “co-morbidity issue”).
As well, some empirical categories have disappeared
from one version to the next, (e.g., homosexuality and
some personality disorders), while others have been intro-
duced (e.g., post-traumatic stress disorder, (PTSD)). Such
categorical variation strongly suggests the need for more
rigorous and evidence-based definition of diseases, as dir-
ectly relevant to clinical diagnoses and treatment(s).
Biopsychosocial model
The biopsychosocial model was first formally proposed
by the psychiatrist George Engel [20] and has been
incorporated - to greater or lesser extent - in the subse-
quent versions of the DSM. The model introduces dis-
tinctions within and between biological, psychological
and social components, and advocates a more holistic
orientation to disease, illness and medical care. However,
post-Engelian interpretations of the biopsychosocial ap-
proach have tended to be somewhat obtuse [21-23]. Eric
Kandel and Antonio Damasio have noted the linked and
interwoven nature of a true biopsychosocial approach,
such that psychiatric care does not belong to a separate
and remote “psychological sphere” but also reflects and
entails biological effects. In the same way, social compo-
nents cannot be considered as completely distinct from
biological and psychological domains.
Meta-structure theory
Instead of a classification based on clinical presentation
(as in DSM-IV, ICD10, and/or PDM), meta-structural tax-
onomy was proposed by Andrews and collaborators [24]
as based on risk factors and intended as a more parsimo-
nious classification. The proposed clusters are: neuro-
cognitive disorders (cluster 1), neuro-developmentaldisorders (cluster 2), psychoses (cluster 3), emotional
disorders (cluster 4), externalizing disorders (cluster 5)
[24]. The proposed axes are only two and currently two
variants exist.
Yet, this approach suffers from many of the same limita-
tions as the previously described orientations.
From categorical approaches to dimensional taxonomies:
Endophenotype theory
An endophenotypic approach represensts a considerable
step further and it is intriguing to note that this model
although proposed for the psychiatric diseases, also may
be extended to other diseases (e.g., diabetes, cancer,
metabolic pathologies, etc.).
The endophenotype makes use of biological markers, de-
scribed using the Buchsbaum criteria (i.e., a biomarker or a
biological trait as a measurable indicator of a disease, which
may be or may be not casual) and the Gottesman-Gould
criteria for diagnosing an endophenotypic trait, which are
that 1) the endophenotype is associated with illness in the
population; 2) the endophenotype is heritable; 3) the
endophenotype is disease state-independent; and 4)
endophenotype and illness co-segregate within families [25].
This is fundamental to the suggested changes we
propose to inform the use of the new DSM-V.
Insights from systems biology, neuroinformatics and
OMICS sciences
We posit that the traditional conception of “homeostasis”
and the difficulty of distinguishing “normal” and an “abnor-
mal” status can be compensated – if not resolved to great
extent – by the idea of a personalized inner dynamical equi-
librium that exist among the genetic and biological compo-
nents, developed and expressed psychological resources
traits and expressions, and the environment. Baselines and
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) system sensitivities and responses vary from person to
person, as well in the same person throughout the life-
span. Thus the shift from a healthy status to a pathological
status is often not a binary condition, but rather reflects a
continuum, wherein disease emerges as a transformation
of the properties of system(s) that have gradually become
less adaptive [26-28].
Not merely focusing on single pieces of the proverbial
puzzle, but instead taking a more comprehensive view of
the picture that entails the systems involved, with and
through approaches from systems biology, neuroinformaticsFigure 2 Gene-gene connections of all genes involved in psychiatric diseand OMICS-based sciences to be implemented in psychi-
atric assessment and treatment [26].
According to etymology, OMICS is derived from the
Sanskrit OM, which means “completeness and fullness”,
and thus, a holistic, systems-oriented approach [29],
which may be well-positioned to fill the gap between the
need for a rigorous and rational psychiatry and the need
for a personalized medicine.
The “Psychiatome”
The interplay of genomics, proteomics, transcriptomics,
toponomics, metabolomics and neuroimaging is emergingases. Edges between nodes represent the known molecular interactions.
Figure 3 Heat-map of psychiatric disease (where SAD stays for
seasonal affective disorder). The color bar indicates the degree of
genomic overlap between a psychiatric disease and another (in
terms of commonly shared genes), being represented in light blue if
weaker and in red if stronger.
Figure 4 Percentages of genes found for each disease after
mining different databases (top) and GO (Gene Onthology)
functional enrichment analysis (bottom). GO, being a set of
semantic associations from biological concepts to specific genes,
enables scientists to make inferences about a particular list/cluster of
genes, from a systems biology perspective, rather than focusing on
a single gene.
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viding patients personalized care. Barabási introduced the
concept of “diseasome” [30] in the context of network
medicine. Herein, we investigate the putative relationships
among and between biological and environmental factors
in psychiatric diseases, in what we call “psychiatome”, in-
spired by the concept of “diseasome”.
Our approach is to assess the shared genes (via mining
through genetic databanks), shared networks (using in-
ferred proteomics data) and shared networks of anatom-
ical regions (i.e. toponomics, exploiting the PubBrain
tool) in such a way as to develop a unique picture of sali-
ent inter-relationships that may subserve or be reflected
by psychiatric disorders.
In attempting re-construct the complex genetic archi-
tecture of the psychiatric disorders (as multi-factorial dis-
eases), we take into account whole-genome association
(WGA) studies, copy-numer variant (CNV), pathways-
based analysis (PBA), micro-arrays-based studies, single
nucleotide polymorphisms (SNPs) studies, quantitative
trait, loci and allelic heterogeneity studies.
Other complex diseases (e.g., heart diseases, diabetes,
asthma, hypertension) are in fact characterized by the in-
volvement of different genes. The possible connections
among different genes involved in our proposed psychia-
tome schema are shown in Figure 2, and the heat-map
matrix depicting relationships among the different psy-
chiatric diseases is represented in Figure 3, with theirrespective gene onthologic (GO) functional enrichment in
Figure 4. Delineating common shared-genes and genomics-
relationships among and between psychiatric diseases can
be useful in shaping the concept of “spectrum” disorder (as
merely a static binary notion of “disease”) and preparation
for use of the new DSM-V in practice [31].
But a truly personalized psychiatry is a broader concept
than simply of pharmacogenomics, genotyping or other
molecular investigations: it also includes the cultural and
spiritual beliefs and practices of the patient [32]. This is
particularly true also because from an evolutionary point
of view, culture and genes have co-evolved such that cul-
ture can influence human genome [33-35], just as the ex-
pression of traits and actions arising from the genome can
affect culture [36], as pictorially shown in Figure 1.
Discussion
In this light, we believe that there is urgent need for a
more comprehensive personalized psychiatric medicine
[37]. Moving from the well-known epidemiological
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considering psychiatric disease from multiple points
of view, given that psychiatric disorders are the result of
complex gene-environment-culture interactions and we
have over-viewed some tools doctors can exploit.
Psychiatric diseases tend to be interrelated (Figures 2
and 3), and exert distinct molecular signatures, and
behavioral markers [38].
Molecular and genomic algorithms [39-41], nanobio-
technologies [42-45], OMICS-derived data and clinical
tests and questionnaires [46] can all be useful to unravel
the ambiguities of psychiatric pathogenesis if – and only
if - combined and integrated.
Classical qualitative approaches have limitations on both
theoretical and pragmatic grounds. Considering a more di-
mensional methodology, could overcome many of these
limitations and thereby be instrumental to improving psy-
chiatric diagnoses and treatments. OMICS sciences, based
on high-throughput technologies, are systems biology re-
lated fields, which in a framework of P5 medicine could
help to establish critical links between psychiatric diseases,
(as disorders with a final common symptomatology with
vastly heterogeneous biological, environmental and socio-
logical underpinnings), and could thereby afford an under-
standing of psychiatric disease beyond classic symptomatic
or syndromal definitions, perhaps leading to better inter-
pretation and use of psychiatric nosology. Perhaps most im-
portantly, by fostering such understanding through OMICS
research, could also enable a meaningfully personalization
of psychiatric care.
Conclusion
In this paper, we offer but an early and limited view to the
potential benefits of OMIC-science in, and for psychiatry.
Further studies must be undertaken to better characterize
the relationships between genes, culture, and environments,
but we hold that a P5-based psychiatry can uphold these
tasks.
We have addressed what we believe to be a gap in
current psychiatric research and practice, namely, the
missing link between OMICS, reclassification of psychi-
atric disorder and personalized medicine. In posing the
importance of incorporating OMICS-based quantitative
dimensional criteria, (supplemental to the classical quali-
tative and categorical approaches), we assert that steps
toward a new psychiatry should include:
1) incorporating OMICS-based data to diagnostic
criteria, taking biological and OMICS-derived
markers not as external validators, but as intrinsic
components of assessment;
2) shift emphasis from reactive, post-hoc assessments,
to more quantitative diagnostic and prognostically
predictive approaches;3) provide bio-psychosocial (and culture-spiritual)
personalized diagnoses and treatments.
Perhaps the “psychiatome” will provide an adequate
translational framework for both psychiatric research
and practice, being holistic and broad, rather than nar-
row and simplistic, even though this promising paradigm
at present is still at an early stage of its development and
implementation.
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